Market Cap 171.17M
Revenue (ttm) 0.00
Net Income (ttm) -108.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,065,100
Avg Vol 848,650
Day's Range N/A - N/A
Shares Out 71.03M
Stochastic %K 42%
Beta 0.86
Analysts Strong Sell
Price Target $12.40

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology
Sector: Healthcare
Phone: 925 407 1049
Address:
1150 Veterans Boulevard, South San Francisco, United States
hopeteen
hopeteen Oct. 25 at 6:46 PM
$NKTX Any prediction for Nkarta’s Presentation at upcoming American College of Rheumatology (ACR) Convergence Meeting ?
0 · Reply
purplesniper
purplesniper Oct. 24 at 4:01 PM
0 · Reply
S_Franconi
S_Franconi Oct. 22 at 8:49 PM
$NKTX Nkarta will present clinical data showing that the company’s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion followed by reconstitution of the B cell compartment, consistent with immune reset in participants with non-Hodgkin lymphoma. Additionally, the company will share data from preclinical studies demonstrating that NKX019 effectively depletes pathogenic B cells in both in vivo lymphoma models and in vitro autoimmune disease models, traffics to lymphoid organs, and disseminates across multiple tissues. These data highlight NKX019’s potential as a novel therapeutic approach for B-cell driven autoimmune diseases. https://finviz.com/news/200310/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting
0 · Reply
Lukey63
Lukey63 Oct. 22 at 3:43 PM
$NKTX all higher risk assets getting killed last two days. Well, most.
0 · Reply
youbi336
youbi336 Oct. 22 at 2:57 PM
$NKTX Abstract of the upcoming presentation on Sunday: https://acrabstracts.org/abstract/nkx019-an-allogeneic-off-the-shelf-cd19-targeting-car-nk-cell-therapy-induces-deep-cd19-b-cell-depletion-in-hematological-malignancy-and-models-of-autoimmune-disease/
0 · Reply
Synkum
Synkum Oct. 21 at 10:47 PM
$NKTX Shawn Rose “Our Nkarta team will be at the American College of Rheumatology Convergence 2025 meeting in my old home Chicago later this week. I am looking forward to seeing all of the exciting scientific advances as well as connecting with partners, colleagues, and friends. ”
0 · Reply
elmono
elmono Oct. 17 at 3:40 PM
$NKTX I couldn’t help myself and buy a token position today…just a few k shares to test the waters…
0 · Reply
Olena
Olena Oct. 17 at 2:31 PM
$NKTX it has uptrend for the last 3 months. Nothing disappointing. Slowly going up towards catalyst
0 · Reply
KiingDrew
KiingDrew Oct. 16 at 7:13 PM
$NKTX $3 soon?
2 · Reply
Doozio
Doozio Oct. 15 at 10:12 PM
$NKTX a 🧠👀 in da FUTUre of 🧠⏰ thru 🧠⏰♾️ n 🐑⏰♾️ because it was always during 🐒🍌🧠⏰♾️
0 · Reply
Latest News on NKTX
Nkarta to Participate in a September Investor Conference

Sep 2, 2025, 8:01 AM EDT - 7 weeks ago

Nkarta to Participate in a September Investor Conference


Nkarta to Participate in an April Investor Conference

Apr 1, 2025, 8:01 AM EDT - 7 months ago

Nkarta to Participate in an April Investor Conference


Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:41 AM EDT - 7 months ago

Nkarta: Grinding Lower, Trying To Find Support


Nkarta: Betting On The Turnaround

Mar 31, 2025, 10:15 AM EDT - 7 months ago

Nkarta: Betting On The Turnaround


Nkarta to Participate in March Investor Conferences

Feb 25, 2025, 8:01 AM EST - 8 months ago

Nkarta to Participate in March Investor Conferences


Nkarta to Participate in an Upcoming Investor Conference

Nov 26, 2024, 7:02 AM EST - 11 months ago

Nkarta to Participate in an Upcoming Investor Conference


Nkarta to Participate in Upcoming Investor Conference

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference


Nkarta: Finally An Attractive Valuation

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation


Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead


Nkarta to Participate in Upcoming Investor Conferences

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences


Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts


Nkarta: Possible Upside From H1 Update, If Positive

Jan 25, 2024, 12:12 PM EST - 1 year ago

Nkarta: Possible Upside From H1 Update, If Positive


Nkarta to Participate at Upcoming Investor Conferences

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences


Nkarta to Participate at Upcoming Investor Conference

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference


hopeteen
hopeteen Oct. 25 at 6:46 PM
$NKTX Any prediction for Nkarta’s Presentation at upcoming American College of Rheumatology (ACR) Convergence Meeting ?
0 · Reply
purplesniper
purplesniper Oct. 24 at 4:01 PM
0 · Reply
S_Franconi
S_Franconi Oct. 22 at 8:49 PM
$NKTX Nkarta will present clinical data showing that the company’s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion followed by reconstitution of the B cell compartment, consistent with immune reset in participants with non-Hodgkin lymphoma. Additionally, the company will share data from preclinical studies demonstrating that NKX019 effectively depletes pathogenic B cells in both in vivo lymphoma models and in vitro autoimmune disease models, traffics to lymphoid organs, and disseminates across multiple tissues. These data highlight NKX019’s potential as a novel therapeutic approach for B-cell driven autoimmune diseases. https://finviz.com/news/200310/nkarta-announces-poster-presentation-at-upcoming-american-college-of-rheumatology-acr-convergence-meeting
0 · Reply
Lukey63
Lukey63 Oct. 22 at 3:43 PM
$NKTX all higher risk assets getting killed last two days. Well, most.
0 · Reply
youbi336
youbi336 Oct. 22 at 2:57 PM
$NKTX Abstract of the upcoming presentation on Sunday: https://acrabstracts.org/abstract/nkx019-an-allogeneic-off-the-shelf-cd19-targeting-car-nk-cell-therapy-induces-deep-cd19-b-cell-depletion-in-hematological-malignancy-and-models-of-autoimmune-disease/
0 · Reply
Synkum
Synkum Oct. 21 at 10:47 PM
$NKTX Shawn Rose “Our Nkarta team will be at the American College of Rheumatology Convergence 2025 meeting in my old home Chicago later this week. I am looking forward to seeing all of the exciting scientific advances as well as connecting with partners, colleagues, and friends. ”
0 · Reply
elmono
elmono Oct. 17 at 3:40 PM
$NKTX I couldn’t help myself and buy a token position today…just a few k shares to test the waters…
0 · Reply
Olena
Olena Oct. 17 at 2:31 PM
$NKTX it has uptrend for the last 3 months. Nothing disappointing. Slowly going up towards catalyst
0 · Reply
KiingDrew
KiingDrew Oct. 16 at 7:13 PM
$NKTX $3 soon?
2 · Reply
Doozio
Doozio Oct. 15 at 10:12 PM
$NKTX a 🧠👀 in da FUTUre of 🧠⏰ thru 🧠⏰♾️ n 🐑⏰♾️ because it was always during 🐒🍌🧠⏰♾️
0 · Reply
Olena
Olena Oct. 15 at 9:44 PM
$TOVX look at $NKTX or $KURA . Institutional hold 90%. Catalysts are near. Good solid stocks
0 · Reply
purplesniper
purplesniper Oct. 15 at 7:23 PM
$NKTX 💎
0 · Reply
nightstocker15
nightstocker15 Oct. 15 at 6:22 PM
$NKTX just steady holding here
0 · Reply
youbi336
youbi336 Oct. 15 at 6:17 PM
0 · Reply
Olena
Olena Oct. 14 at 8:58 PM
$NKTX https://www.zacks.com/stock/research/NKTX/price-target-stock-forecast
0 · Reply
Olena
Olena Oct. 14 at 8:29 PM
$NKTX steadily going up towards a catalyst
0 · Reply
Olena
Olena Oct. 14 at 7:38 PM
$NKTX The main upcoming catalyst for Nkarta, Inc. (NKTX) is the presentation of clinical data from its Ntrust-1 and Ntrust-2 trials for the therapy NKX019. These upcoming trials are expected to provide preliminary data and updates on NKX019's efficacy and safety for autoimmune diseases and have the potential to lead to further FDA designations, strategic partnerships, or acquisition interest if the results are positive. Upcoming clinical catalysts Data from Ntrust-1 and Ntrust-2 trials: The company anticipates releasing preliminary clinical data from these trials in the second half of 2025. Focus on autoimmune diseases: The Ntrust-2 trial will explore the potential of NKX019 in autoimmune conditions like systemic sclerosis, myositis, and vasculitis. Potential for positive results: Positive data could demonstrate durable remissions, provide safety and efficacy metrics, and partially validate the technology for autoimmune disorders. Possibility of FDA designations:
0 · Reply
purplesniper
purplesniper Oct. 14 at 4:43 PM
0 · Reply
youbi336
youbi336 Oct. 14 at 4:11 PM
$NKTX Looks like it'll finally break the 200 EMA
0 · Reply
youbi336
youbi336 Oct. 10 at 3:43 PM
$NKTX Big rejection from the 200 EMA on relatively low volume
0 · Reply
McGinvests
McGinvests Oct. 10 at 3:36 PM
$CRDF just getting pounded today 😫 $QNCX $NKTX
2 · Reply
Benitocalixto
Benitocalixto Oct. 10 at 2:02 PM
$NKTX there's this.. https://www.dailymail.co.uk/health/article-15173979/cancer-treatment-discovered-natural-harvard-mit.html
0 · Reply